Electronic Fetal Heart Rate Monitoring: The Future
Taran Khangura and Edwin Chandraharan
Pages 169-174 (6)
Continuous electronic fetal heart rate monitoring (EFM) using a cardiotocograph (CTG) is associated with a
high false positive rate of approximately 60%. Current scientific evidence does not support a significant reduction in
perinatal mortality or cerebral palsy, except for a 50% reduction in neonatal convulsions. Recent scientific evidence has
questioned the role of ‘peripheral’ tests of fetal wellbeing such as fetal scalp blood sampling (FBS), fetal scalp lactate and
fetal pulse oximetry in reducing the false positive rate of CTG. Fetal ECG (ST-Analyzer or STAN) shows promise in
reducing neonatal admissions and operative vaginal births. Computerized CTG analysis and Fetal Physiological Score
(FPS) may help reduce errors associated with CTG interpretation.
Fetal scalp blood sampling, fetal scalp lactate, ST-Analyzer (STAN), Fetal Physiological Score (FPS),
Consultant Obstetrician and Gynaecologist, St. George’s Healthcare NHS Trust, Blackshaw Road, London SW 17 0RE, UK.